Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 1.15% is 126% above its 5-year average of -4.44%, near the high end of its 5-year range (-13.18%–3.74%).
41.91% below its 12-month average of 1.98%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): 3.74%.
EBITDA MARGIN
1.15%
EBITDA MARGIN AVG TTM
1.98%
EBITDA MARGIN AVG 3Y
-1.40%
EBITDA MARGIN AVG 5Y
-4.44%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-41.91%
CURRENT VS 3Y AVG
+182.34%
CURRENT VS 5Y AVG
+125.88%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Alignment Healthcare, Inc.
Market Cap
$1.76B
EBITDA Margin
1.15%
TTM Avg
1.98%
3Y Avg
-1.40%
5Y Avg
-4.44%
Market Cap
$1.78B
EBITDA Margin
-628.14%
TTM Avg
-766.74%
3Y Avg
-948.44%
5Y Avg
-801.32%
Market Cap
$1.78B
EBITDA Margin
-695.72%
TTM Avg
-791.65%
3Y Avg
-791.65%
5Y Avg
-791.65%
Market Cap
$1.71B
EBITDA Margin
16.41%
TTM Avg
1.22%
3Y Avg
-1.65%
5Y Avg
4.31%
Market Cap
$1.66B
EBITDA Margin
-164.52%
TTM Avg
-214.39%
3Y Avg
-473.06%
5Y Avg
-473.06%
Market Cap
$1.87B
EBITDA Margin
-864.28%
TTM Avg
-1007.63%
3Y Avg
-1530.50%
5Y Avg
-1530.50%
Market Cap
$1.65B
EBITDA Margin
19.54%
TTM Avg
15.33%
3Y Avg
15.07%
5Y Avg
12.91%
Market Cap
$1.65B
EBITDA Margin
0.06%
TTM Avg
-4.29%
3Y Avg
-15.38%
5Y Avg
-22.40%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Alignment Healthcare, Inc. (ALHC) | $1.76B | 1.15% | 1.98% | -1.40% | -4.44% |
| Intellia Therapeutics, Inc. (NTLA)vs › | $1.78B | -628.14% | -766.74% | -948.44% | -801.32% |
| Generate Biomedicines, Inc. (GENB)vs › | $1.78B | -695.72% | -791.65% | -791.65% | -791.65% |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $1.71B | 16.41% | 1.22% | -1.65% | 4.31% |
| Astrana Health, Inc. (ASTH)vs › | $1.83B | 3.91% | 4.83% | 6.92% | 8.21% |
| Kestra Medical Technologies, Ltd. (KMTS)vs › | $1.66B | -164.52% | -214.39% | -473.06% | -473.06% |
| Agios Pharmaceuticals, Inc. (AGIO)vs › | $1.87B | -864.28% | -1007.63% | -1530.50% | -1530.50% |
| ANI Pharmaceuticals, Inc. (ANIP)vs › | $1.65B | 19.54% | 15.33% | 15.07% | 12.91% |
| Alphatec Holdings, Inc. (ATEC)vs › | $1.65B | 0.06% | -4.29% | -15.38% | -22.40% |
| BioLife Solutions, Inc. (BLFS)vs › | $1.89B | 3.75% | 2.81% | -0.66% | -2.07% |
Gross Margin
12.6%
EBITDA Margin
1.1%
Operating Margin
1.2%
Net Margin
0.9%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 3.74% |
| 2026-03-31 | 1.89% |
| 2025-12-31 | -0.24% |
| 2025-09-30 | 1.58% |
| 2025-06-30 | 2.93% |
| 2025-03-31 | 0.24% |
| 2024-12-31 | -2.24% |
| 2024-09-30 | -1.71% |
| 2024-06-30 | -1.74% |
| 2024-03-31 | -5.58% |
| 2023-12-31 | -7.75% |
| 2023-09-30 | -5.30% |
| 2023-06-30 | -3.98% |
| 2023-03-31 | -6.26% |
| 2022-12-31 | -13.09% |
| 2022-09-30 | -8.02% |
| 2022-06-30 | -0.66% |
| 2022-03-31 | -9.40% |
| 2021-12-31 | -13.18% |
| 2021-09-30 | -12.72% |
| 2021-06-30 | -11.82% |
| 2021-03-31 | -18.30% |
| 2020-12-31 | -9.75% |
| 2020-09-30 | 7.70% |
| 2020-06-30 | 6.63% |
| 2020-03-31 | -0.64% |
